18,211 13,598
Property, plant and equipment, net 10,494 7,131
Other assets 43,725 44,410
Total assets $609,399 $258,858
Liabilities, noncontrolling interest and
stockholders' equity:
Other current liabilities $25,604 $29,000
Current portion of deferred contract revenue 101,507 33,205
2 5/8% convertible subordinated notes 162,500 162,500
Long-term obligations, less current portion 5,415 362
Long-term deferred contract revenue 214,202 23,548
Noncontrolling interest in Regulus
Therapeutics LLC 7,523 9,371
Noncontrolling interest in Ibis Biosciences, Inc. 33,625 -
Stockholders' equity 59,023 872
Total liabilities, noncontrolling interest
and stockholders' equity $609,399 $258,858
'/>"/>SOURCE Isis Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Related biology technology :1.
Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share2.
PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results3.
Caliper Life Sciences Reports Second Quarter 2008 Results4.
Watson Pharmaceuticals Reports Second Quarter 2008 Results5.
EntreMed Reports Second Quarter 2008 Financial Results6.
Transgenomic Reports Second Quarter 2008 Results7.
Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results8.
Bionovo Reports Second Quarter 2008 Financial Results9.
AtriCure Reports Record Second Quarter 2008 Financial Results10.
AMICAS Reports Financial Results for the Second Quarter Ended June 30, 200811.
eResearchTechnology Reports Second Quarter 2008 Results